The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.
Male and female ages between ages 18-60 years.
Ability to give written informed consent (age 18 or above).
Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.
Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3.
Inability to sign informed consent.
Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions.
Significant alcohol or other drug use other than nicotine or marijuana dependence.
Inability to refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
The University of Texas Health Science Center, Houston
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator